Tickr
Home Explore Daily Brief Market Watchlists Portfolio
Research
Catalysts Signal Factory Screener Market News Event Calendar Valuation Plot Heat Map Top Investors Industry Trends Options
AI Assistant Notifications Account
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) Stock Ticker

NASDAQ: PYXS · Healthcare · Biotechnology
$2.90+1.40%
USD · as of 2026-09-29 · market cap $183.7M
Open PYXS in TickrDownload for iPhone

PYXS right now

Growing revenue 291% a year on 100% gross margins.
Options expect by Oct 6±21.1%
Options expect by Oct 29±43.7%
Priced in for Nov 2 earnings±46.5%
IV rank (30-day)66% · fair
From Tickr's live models · 2026-09-29. Not investment advice.

Market factors today

Tickr 500 vs S&P 500+0.49%+1.0% MTD
Momentum L/S+1.35%+15.1% MTD
High-beta momo L/S+1.46%+22.2% MTD
Rate sensitivity L/S+1.91%+6.9% MTD
Oil sensitivity L/S-2.54%-5.3% MTD
Unprofitable tech-1.43%+3.7% MTD

Unlock the full PYXS picture

🔒 Implied move chart & probabilities
🔒 Live options flow
🔒 AI analysis & chat on PYXS
🔒 Catalysts & earnings
🔒 Strategy Lab
🔒 Financials & estimates
Start your 7-day free trial

About Pyxis Oncology, Inc.

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

PYXS stock facts

Ticker symbolPYXS
ExchangeNASDAQ Global Select
SectorHealthcare
IndustryBiotechnology
Market cap$183.7M
CEOThomas Civik
Employees56
HeadquartersBoston, MA, US
IPO date2021-10-08
Websitewww.pyxisoncology.com

What you can see for PYXS on Tickr

Live PYXS price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the PYXS report.

Rankings

Largest Healthcare companiesLargest companies by market cap

FAQ

What is the ticker symbol for Pyxis Oncology, Inc.?

The ticker symbol for Pyxis Oncology, Inc. is PYXS, listed on the NASDAQ Global Select.

What is PYXS?

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous…

HomeExploreMarketLists
All pages